Monoclonal antibody capable of binding to anexelekto, and use thereof
The present inventors have succeeded in producing anti-AXL antibodies with specific functions. The present inventors also discovered that the antibodies have an angiogenesis-suppressive effect and an antitumor effect, and thereby completed the present invention. The anti-AXL antibodies of the present invention are useful as angiogenesis inhibitors and agents for inducing or inhibiting phosphorylation activity.
1. A monoclonal anti-AXL antibody according to any of the following (a) to (b):
(a) a monoclonal antibody (Ax284) produced from a hybridoma deposited with the International Patent Organism Depositary (IPOD), National Institute of Advanced Industrial Science and Technology (AIST) and assigned Accession No. FERM BP-10857; and
(b) a monoclonal antibody (Ax225) produced from a hybridoma deposited with the IPOD, AIST, and assigned Accession No. FERM BP-10854.
2. A monoclonal anti-AXL antibody that binds to the same epitope bound by either of
(a) a monoclonal antibody (Ax284) produced from a hybridoma deposited with the IPOD, AIST, and assigned Accession No. FERM BP-10857; or
(b) a monoclonal antibody (Ax225) produced from a hybridoma deposited with the IPOD, AIST, and assigned Accession No. FERM BP-10854.
3. A monoclonal anti-AXL antibody that comprises heavy chain CDR1, 2, and 3 amino acid sequences corresponding to SEQ ID NOs: 4, 5, and 6, respectively; and light chain CDR1, 2 and 3 amino acid sequences corresponding to SEQ ID NOs: 8, 9 and 10, respectively.
4. The anti-AXL antibody according to claim 3 , wherein the antibody is a chimeric antibody.
5. The anti-AXL antibody according to claim 3 , wherein the antibody is a humanized antibody.
6. An isolated hybridoma according to any of the following (a) to (b):
(a) an isolated hybridoma deposited with IPOD, AIST, and assigned Accession No. FERM BP-10857 (Ax284); and
(b) an isolated hybridoma deposited with the IPOD, AIST, and assigned Accession No. FERM BP-10854 (Ax225).
7. A monoclonal anti-AXL antibody that competes for binding to the same epitope bound by either of
(a) a monoclonal antibody (Ax284) produced from a hybridoma deposited with the IPOD, AIST, and assigned Accession No. FERM BP-10857; or
(b) a monoclonal antibody (Ax225) produced from a hybridoma deposited with the IPOD, AIST, and assigned Accession No. FERM BP-10854.